The latest advance in surgical technique seems of great value to Nuvo. Clinical trials have proved that the excision of a pair of cancerous CEO's is sufficient to halt the haemorrhage of profit. Replacement by a single, qualified individual that lacks the thirst for the company's lifeblood is seen to return the patient to its previous healthy state.

I shall bring my scalpel to the AGM.